A detailed history of Quadrant Capital Group LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 251 shares of KROS stock, worth $4,332. This represents 0.0% of its overall portfolio holdings.

Number of Shares
251
Holding current value
$4,332
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$13.34 - $16.05 $3,348 - $4,028
251 New
251 $3,000
Q2 2023

Aug 09, 2023

BUY
$37.26 - $51.01 $223 - $306
6 New
6 $0

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $445M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.